Oxford Cancer Vaccine Hub
Our mission is to develop preventative and therapeutic targets and expediate the design, manufacture and testing of both personalised and off-the-shelf cancer vaccines.
The Oxford Cancer Vaccine Hub facilitates innovation from multiple research groups, and aims to achieve transformative benefits in the treatment of multiple cancer types (‘therapeutic vaccines’) as well as preventing cancer development/recurrence in people at clinically defined higher risk (‘precision prevention vaccines’).
At the heart of the Oxford Cancer Vaccine Hub are patient-driven priorities. We have run a series of events to ask the public what matters most to them and their concerns so that we can prioritise our work accordingly.
To work effectively we have research groups and units spanning the whole vaccine development pipeline from pre-clinical biology through to interventional studies, including target selection and vaccine design. Within Oxford we have ample clinical and scientific leadership and access to bespoke patient samples and high-risk cohorts. We also partner with a range of other academic institutions, industry and hospitals to undertake research delivering cutting-edge benefits to patients.
We have a seamless workflow brought together by linked research groups with specialist expertise in:
- Antigen discovery and cancer immunology
- Vaccine design and preclinical validation
- Clinical grade vaccine manufacture
- Cancer vaccine clinical Trials in patients and high risk healthy individuals
In addition to developing therapeutic vaccines and testing them in novel combinations, Oxford is the only UK clinical trials unit focused on precision prevention of cancer and we are developing a portfolio of vaccine trials designed to lower cancer incidence in healthy individuals.
The hub is being developed in close partnership with Dr Lennard Lee, who has been instrumental in the Cancer Vaccine Launch Pad whilst on secondment to the Office for Life Sciences.
Patient and public involvement and engagement
Sustained and creative patient and public involvement and engagement (PPIE) is critical to the success of the cancer vaccinations programme.
Our researchers will be guided and supported by Oxford Cancer’s growing community of PPIE contributors, developing strategic interdisciplinary partnerships across the University, and working with local and national community groups.